Výsledky vyhledávání - "Aurelie Belleville"

Does a homeopathic medicine reduce hot flushes induced by adjuvant endocrine therapy in localized breast cancer patients? A multicenter randomized placebo-controlled phase III trial

Autor: Aurelie Belleville, David Pérol, Laetitia Stefani, Lionel Vincent, Dominique Dramais, Emilie Lavergne, Isabelle Van Praagh-Doreau, Bernard Duvert, Ellen Blanc, Pierre-Etienne Heudel, Jean-Paul Guastalla, Anne-Claire Hardy-Bessard, Jean-Philippe Jacquin, Isabelle Cauvin

Publikováno v: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 27(5)

Endocrine therapy (ET) used to reduce the risk of recurrence in hormone receptor-expressing disease (75% of breast cancers) is associated with worsening of climacteric symptoms with a negative impact on quality of life (QoL). Homeopathy might allow a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae054a4b752e6185e497ac97a9c024bb
https://pubmed.ncbi.nlm.nih.gov/30194492

Zobrazit plný text záznamu

Can a homeopathic medicine complex reduce hot flashes induced by adjuvant endocrine therapy in localized breast cancer patients? Results of a randomized placebo-controlled phase III trial

Autor: Lionel Vincent, Bernard Duvert, Isabelle Van Praagh, Laetitia Stefani, Anne-Claire Hardy-Bessard, Pierre-Etienne Heudel, Emilie Lavergne, Aurelie Belleville, Jean-Philippe Jacquin, Isabelle Cauvin, Ellen Blanc, Jean-Paul Guastalla, Aurelie Belliere, David Pérol, Dominique Dramais

Publikováno v: Journal of Clinical Oncology. 33:9627-9627

9627 Background: Homeopathy is already used for the management of menopausal hot flashes (HF) and could reduce this frequent endocrine therapy’s (ET) side effect. Methods: Localized breast cancer p...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8dd10074785a20a5606b82bad085d7cd
https://doi.org/10.1200/jco.2015.33.15_suppl.9627

Zobrazit plný text záznamu

Final results of the multicenter randomized phase II PAZOGIST trial evaluating the efficacy of pazopanib (P) plus best supportive care (BSC) vs BSC alone in resistant unresectable metastatic and/or locally advanced gastrointestinal stromal tumors (GIST)

Publikováno v: Journal of Clinical Oncology. 33:10506-10506

10506 Background: GIST is the most common mesenchymal neoplasm of the gastrointestinal tract. Imatinib followed by sunitinib then regorafenib is the usual sequence in advanced setting. P is effecti...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::27e89d970c36ff63a24b051cd34206f3
https://doi.org/10.1200/jco.2015.33.15_suppl.10506

Zobrazit plný text záznamu

A Randomized Multicentre Phase Ii Study of Pazopanib Plus Best Supportive Care (Bsc) Vs Bsc Alone in Metastatic Gastrointestinal Stromal Tumors (Gist) Resistant to Imatinib and Sunitinib

Publikováno v: Annals of Oncology. 25:v1

Aim: GIST is the most common mesenchymal neoplasm of the gastrointestinal tract. In unresectable and metastatic or locally advanced disease, imatinib followed by sunitinib, then regorafenib represent the standard treatments in 1st, 2nd and 3rd line,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8cf2ea5f8f30893f0c4374e046374879
https://doi.org/10.1093/annonc/mdu438.57

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání